Current osteosarcoma therapies cause severe treatment-related side effects and chemoresistance, and have low success rates. Consequently, alternative treatment options are urgently needed. Photodynamic therapy (PDT) is a minimally invasive, local therapy with proven clinical efficacy for a variety of tumor types. PDT is cytotoxic, provokes anti-vascular effects and stimulates tumor cell targeting mechanisms of the immune system and, consequently, has potential as a novel therapy for osteosarcoma patients. This study investigated the uptake and the dark-and phototoxicity and cytotoxic mechanisms of the photosensitizer (PS) 5,10,15,20-tetrakis(-meta-hydroxyphenyl) chlorine (mTHPC, Foscan) and a liposomal mTHPC formulation (Foslip) in the human 143B and a mouse K7M2-derived osteosaroma cell line (K7M2L2) in vitro. Second, the tumor-and metastasis-suppressive efficacies of mTHPC formulations based PDT and associated mechanisms in intratibial, metastasizing osteosarcoma mouse models (143B/SCID and syngeneic K7M2L2/BALB/c) were studied. The uptake of Foscan and Foslip in vitro was time-and dose-dependent and resulted in mTHPC and light dose-dependent phototoxicity associated with apoptosis. In vivo, the uptake of both i.v. administered mTHPC formulations was higher in tumor than in healthy control tissue. PDT caused significant (Foscan p < 0.05, Foslip p < 0.001) tumor growth inhibition in both models. A significant (Foscan p < 0.001, Foslip p < 0.001) immune system-dependent suppression of lung metastasis was only observed in the K7M2L2/BALB/c model and was associated with a marked infiltration of T-lymphocytes at the primary tumor site. In conclusion, mTHPC-based PDT is effective in clinically relevant experimental osteosarcoma and suppresses lung metastasis in immunocompetent mice with beneficial effects of the liposomal mTHPC formulation Foslip.
Osteosarcoma is the most common primary high-grade bone neoplasm and one of the deadliest cancer types in children and adolescents. 1, 2 Since the introduction of new treatment protocols in the 70ies, including neoadjuvant and adjuvant chemotherapy, the 5-year survival rate (5-ysr) of patients with localized disease increased significantly to approximately 60% but plateaued ever since. 3, 4 However, patients with metastatic disease, with lesions most frequently developing in the lungs and other bones, continue to have a poor 5-ysr of approximately 30%. 5 Unfortunately, multi-drug therapy, using high-dose methotrexate, cisplatin, and doxorubicin, is associated with a variety of severe side effects ranging from gastrointestinal problems, neutropenia, cardiac toxicity, neurological dysfunction, second malignant neoplasms to even death. 6, 7 Although multi-agent chemotherapy increased the survival of patients, it plateaued over the last three decades, most probably owing to the high tumor heterogeneity of osteosarcoma and to chemoresistance. 8, 9 The lack of novel, more effective therapeutic strategies for metastasizing osteosarcoma has become an increasing problem. During the last four decades, photodynamic therapy (PDT) evolved into a novel attractive treatment option for a variety of cancer types. 10 PDT is a multi-step process making use of three components; photosensitizer (PS), light and oxygen. 11 In a first step of the therapy, PS is injected into the blood stream and is taken up by tumor and also by healthy cells. Next, tumor-selective PDT is achieved by local illumination of the tumor site with light, which activates the lightsensitive PS to a higher energy state and results in the direct or indirect transfer of excess energy to neighboring oxygen molecules or tissue molecules, producing cell-toxic reactive oxygen. Finally, in addition to eliciting direct cytotoxicity, PDT provokes a variety of additional beneficial anti-tumor effects such as an acute inflammatory response, anti-vascular effects and an activation of the immune system. 11 PDT has commonly been used for the treatment of solid tumors at superficial anatomical locations, however, its application in other tumors at more inaccessible sites has become an aim of clinical investigations. 12, 13 Additionally to the advantage of PDT as a local application, also a systemic immune response against tumors have been reported, [14] [15] [16] therefore PDT is potentially not only effective against local tumor growth but also against distant metastases.
PDT is associated with good functional and aesthetic outcomes and clinical studies reported it as a good treatment option for patients unsuitable for other treatments in head and neck cancers, 17, 18 but studies investigating potential therapeutic applications in osteosarcoma are scarce. In vitro investigations demonstrated strong cytotoxic effects of PDT in different osteosarcoma cells lines. [19] [20] [21] [22] Preclinical studies in osteosarcoma mouse models showed an inhibition of local tumor growth, 23, 24 but these studies were either performed in subcutaneous osteosarcoma mouse models, which do not reproduce the clinical situation, or in immune suppressed mice, where the impact on distant metastases cannot be evaluated. Nevertheless, a preclinical study by Burch et al. who applied PDT in dogs that spontaneously developed osteosarcoma, demonstrated substantial tumor necrosis, indicating the potential of PDT for effective treatment of osteosarcoma, but long-term effects or treatment impact on metastases were not reported. 25 One of the most powerful and commonly used PS is 5,10,15,20-tetrakis(meta-hydroxyphenyl)chlorine (mTHPC), traded under the name FoscanV R . Although mTHPC is a potent PS, its high hydrophobicity restricts the routes of administration. Encapsulation of mTHPC into liposomal structures, however, achieved with the formulation Foslip used in this study, makes it water soluble, which potentially increases PDT efficacy. [26] [27] [28] In this study, we investigated the uptake and the darkand phototoxicity of Foscan and Foslip in the human 143B and in a derivative (K7M2L2) of the mouse K7M2 osteosarcoma cell line. In addition, we studied the efficacies of Foscan-and Foslip-based PDT in a 143B cell line-dependent intratibial xenograft osteosarcoma model in SCID mice and in an intratibial K7M2L2 cell line-derived model in syngeneic, immune competent BALB/c mice. Tumors in both models metastasize to the lung. Thus, these models allowed us to compare the tumor-and metastasis-suppressive potential of Foscan-and Foslip-based PDT in the absence and in the presence of a functional immune system. The results demonstrated promising tumor and immune system-dependent metastasis suppressive effects and anti-vascular activity of the here applied PDT in a clinically relevant experimental osteosarcoma model.
Material and Methods

Photosensitizer and OS cell lines
Foscan and Foslip were kindly provided by Biolitec research GmbH (Jena, Germany). Foscan was reconstituted and diluted in ethanol (40% w/w) and propylene glycol (60% w/w). Foslip, a liposomal formulation of mTHPC, is a 9:1 mixture of dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG; >99% purity). Foslip (freeze-dried product) was reconstituted with water to 1.5 mg mTHPC/ml and further diluted in 5% glucose.
Human 143B osteosarcoma cells were purchased from ECACC (Salisbury, UK) and murine K7M2 osteosarcoma cells (CRL-2836) were kindly provided by Dr. Chand Khanna (Center for Cancer Research National Institute, Bethesda). Cells were cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1) medium (Invitrogen, Carlsbad, CA), supplemented with 10% heat-inactivated FCS (GIBCO, Basel, Switzerland), at 378C in a humidified atmosphere of 5% CO 2 air.
Both cell lines were transduced with a lacZ reporter gene. 29 19 24 hrs later, the cell viability was measured with the water-soluble tetrazolium (WST-1) assay (Roche, Basel, Switzerland) according to the manufacturer's protocol.
Western blot analysis of apoptosis
10
6 143B or K7M2L2 cells were seeded in 6 cm cell culture dishes. After overnight adherence, cells were incubated under tissue culture conditions for 5 hr with Foscan or Foslip (0.6 mg/ml mTHPC) and pre-incubated for 1 hr with or without the pan-caspase inhibitor Z-VAD-FMK (100 mM) or its solvent control (1% DMSO) (BD Pharmingen AG, Allschwil, Switzerland). Cells were illuminated and protein extracts were analyzed for PARP and cleaved PARP (1:1,000, Cell Signaling Technology) and GAPDH (protein loading control) (1:3,000, Santa Cruz Biotechnologies, TX) as previously described. 19 Intratibial human xenograft and syngeneic osteosarcoma mouse models All studies were conducted with the approval of the Veterinary Office Kanton Zurich, Switzerland (animal application license 167/2012) and in accordance with the guidelines of the Swiss Federal Veterinary Office. Eight-week-old female SCID and BALB/c mice were obtained from Charles River Laboratories. 10 5 143B/lacZ cells in 10 ml PBS/0.05% EDTA were injected i.t. into SCID mice (143B/SCID) (human xenograft mouse model) and 10 5 K7M2L2/lacZ cells in 10 ml PBS/ 0.05% EDTA i.t. into BALB/c mice (K7M2L2/BALB/c) (syngeneic mouse model) as previously described. 30 In vivo uptake of Foscan and Foslip by intratibial tumors Upon formation of a tumor (>50 mm 3 ), Foscan or Foslip at doses equivalent to 1.5 mg/kg mTHPC were administered to the mice (143B/SCID n 5 10, K7M2L2/BALB/c n 5 14) with a slow (4-6 min) intravenous (i.v.) injection in the tail vein. The mice were then kept in a darkened environment for the rest of the experiment. The area of the leg where the tumor was localized was shaved and the mTHPC uptake by the tumor was measured with a PDT fluorometer (JETI Technische Instrumente GmbH, Jena, Germany) in three different locations on the surface of the skin covering the tumor (excitation 405 nm, emission 550-800 nm). Background fluorescence of intratibial tumor tissue was measured (integration time 7,500 ms) in a mouse without PS injection and was subtracted from each measurement resulting in RFU. The mean RFU of the tumor in individual PS-injected mice was calculated from all three emission peak values detected at 652 nm. Upon sacrifice, tumors were cut longitudinally into halves and mTHPC fluorescence was measured inside the tumor tissue in three different locations as described above.
PDT protocol
In both, the xenograft and the syngeneic osteosarcoma model, the mice were randomly assigned to three groups; a control group receiving PS but no illumination (143B/SCID n 5 10, K7M2L2/BALB/c n 5 15), a group receiving Foscanbased PDT (143B/SCID n 5 7, K7M2L2/BALB/c n 5 8) and a group that was subjected to Foslip-based PDT (143B/SCID n 5 7, K7M2L2/BALB/c n 5 9). Foscan or Foslip control mice revealed no difference in any experimental analyses and were therefore merged and presented as one control group (data not shown). A control group of mice that were only illuminated without PS injection was not included here since preliminary studies showed no effect of illumination alone on tumor development (data not shown). Treatment was started after the formation of a tumor (>50 mm 3 ). Both legs were shaved and the mice were injected with Temgesic (i.p., 0.1 mg/kg). Foscan or Foslip (mTHPC 0.15 mg/kg) were administered by i.v. injection (4-6 min). The mice were kept in a darkened environment for the rest of the experiment. 24 hr after mTHPC injection, the mice were anaesthetized (1-5% isoflurane/O 2 ) and covered with aluminum foil and black paper such that only the primary tumor within the left hind leg was exposed. The tumors in the PDT groups were illuminated at an energy dose of 20 J/cm 2 (26.817 mW/cm 2 , 720 sec) with a 652 nm diode laser (Applied Optronics Corp., South Plainfield, NJ), equipped with a fiber-based frontal light distributor (Medlight SA, Ecublens, Switzerland). Primary tumor growth over time after PDT was monitored by caliper ruler measurements at indicated time points and the data are presented as tumor volume fold-change, comparing the tumor volume in individual mice with the respective volume on the day of PDT.
In the xenograft model (143B/SCID), the mice were sacrificed 14 days after PDT. In the syngeneic model (K7M2L2/ BALB/c), three mice per group were sacrificed 2 days after illumination for histological analyses of tumor tissue; all other mice were sacrificed 10 days after PDT.
Pulmonary metastases
After sacrifice of the mice in situ, lung perfusion was performed. The lungs were dissected and stained with X-gal for lacZ-transduced tumor cells as previously described. 32 Histological analyses in tumor-bearing BALB/c mice mTHPC fluorescence in primary tumor tissue. Pieces of primary tumor tissue were embedded in mounting medium (Dako, Denmark) and snap frozen in liquid nitrogen. mTHPC in 10 mm sections of primary tumor tissue was visualized with an AxioCam MRm camera connected to a Zeiss Observer.Z1 inverted microscope (Carl Zeiss MicroImaging GmbH) set to 4x magnification and equipped with a fluorescent filter for excitation at 488 nm and detection of emission at 600-700 nm.
Histological staining. Tumor tissue dissected from the hindlimb at sacrifice was fixed in 4% paraformaldehyde and subsequently decalcified in Osteosoft (Merck Millipore, Germany). The tumors were trimmed, dehydrated in graded alcohol and embedded in paraffin according to standard protocols. Sections of 5-10 mm were mounted on glass slides, deparaffinized in xylene, rehydrated in graded alcohol and stained with hematoxylin and eosin (HE).
Tumor necrosis was assessed in the HE-stained sections as follows: Grade 0: no necrosis; Grade 1: necrosis below 20%; Grade 2: necrosis > 20% and < 40%; Grade 3: necrosis > 40% and < 60%; Grade 4: necrosis > 60% and <80%; Grade 5: necrosis > 80%. Apoptosis was assessed by immunostaining with an antibody to cleaved caspase 3 (Cell Signaling) and tumor vascularization by staining with an antibody to CD31 (Santa Cruz Biotechnologies), a cell surface marker of endothelial cells. 33 The number of apoptotic cells present in tumor sections was normalized to the total number of cells (apoptotic index 34 ). Visiomorph software (Visiopharm, Denmark) was employed to calculate the apoptotic index was determined by counting at least 2,500 cells in randomly selected areas of tumor tissue sections free of necrosis. Numbers of T (CD3 immunostaining, Spring Biosciences) and B (CD45R immunostaining, BD Biosciences) lymphocytes were counted with the same software in 20 high power fields (HPF) randomly selected in the core and at the periphery of the tumors, avoiding areas of frank necrosis, and in the lungs. Data are presented as the mean (6 SEM) number of stained cells/HPF.
Assessment of hind limb blood vessel perfusion
Mice were anesthetized (1-5% isoflurane) and placed in supine position under the laser Doppler perfusion imager (Moor instruments, UK). Tissue perfusion was measured before PDT and 2, 7 and 10 days after illumination at a speed of 4 ms/pixel using moorLDI Measurement v6.0 software (Moor instruments, UK). The results were analyzed by drawing a region of interest (ROI) around areas of tumor growth and the corresponding contralateral region in the control limb (normal tissue) using moorLDI Review v6.0. The branching of the epigastric vein from the femoral vein and the branching of the caudal femoral vein were used as anatomical landmarks to define the ROI. The percent difference in perfusion of tumor compared to normal tissue was calculated using the following formula: (1-(flux normal /flux tumor )) 3 100.
Statistical analysis
In vitro experiments show results of three independent experiments. The results are presented as the mean 6 standard error of the mean (SEM) if not described otherwise. Statistical significance of differences between groups was determined using one-way ANOVA with Bonferroni post hoc test. Two-way repeated measures ANOVA with Bonferroni's post-test analysis was used to compare mTHPC uptake in vitro and in vivo and treatment efficacy (tumor volume, blood vessel perfusion). Statistical analyses were performed using GraphPad Prism Version 5.01 software (GraphPad Software). A p values below 0.05 was considered to be statistically significant.
Results
Cellular uptake of Foscan and Foslip in osteosarcoma cell lines
In both human 143B and murine K7M2L2 osteosarcoma cells, Foscan and Foslip were taken up in a dose-and timedependent manner (Figs. 1a and 1b) . No differences in cellular uptake of Foscan and Foslip were observed at mTHPC concentrations up to 10 mg/ml (Fig. 1a) . In time course experiments, both the 143B and K7M2L2 cell lines exhibited a slightly delayed uptake of Foslip compared to Foscan, but the difference was no longer significant after 48 hr of incubation (Fig. 1b) . Confocal laser scanning microscopy of 143B and K7M2L2 cells incubated with Foscan and Foslip showed a cytoplasmic localization of mTHPC, but no mTHPC in the nucleus (Fig. 1c) .
Cytotoxicity of Foscan and Foslip
To investigate differences in photo-and dark-toxicity of Foscan and Foslip in 143B and K7M2L2 osteosarcoma cells, the cells were incubated with the mTHPC formulations at indicated mTHPC concentrations. Foscan exhibited a dosedependent dark-toxicity in 143B and K7M2L2 cells with halfmaximal inhibitory doses (IC 50 ) equivalent to 11.74 and 10.4 mg/ml mTHPC, respectively (Fig. 2a) . In contrast, Foslip showed no detectable dark-toxicity in both cell lines. Both, Foscan and Foslip showed mTHPC and a laser light dosedependent phototoxicity (Fig. 2b) 
Cancer Therapy and Prevention
Both Foscan and Foslip-based treatment induced apoptotic cell death, shown by the presence of cleaved PARP in extracts of cells subjected to PDT in both 143B (Fig. 2c ) and K7M2L2 cells (Fig. 2d) . In both cell lines, PARP cleavage was suppressed by pretreatment of the cells with the pan-caspase inhibitor Z-VAD-FMK prior to PDT, indicating a caspase dependent apoptosis pathway, confirmed by the detection of cleaved of caspase 3, 7 and 9 in the cell extracts (Supporting Information Figs. 1a and 1b) .
In vivo uptake of Foslip and Foscan by primary tumors in the xenograft and syngeneic osteosarcoma mouse models
In order to compare the uptake of the mTHPC formulations Foscan and Foslip by intratibial primary tumors in the xenograft 143B/SCID and the syngeneic K7M2L2/BALB/c osteosarcoma mouse models, the PS formulations were i.v. injected into respective tumor-bearing mice. The uptake by tumor tissue was monitored in vivo during 48 hr and subsequently analyzed ex vivo. In both models, the two mTHPC formulations were taken up by the tumor tissue in a time dependent manner (Figs. 3a and 3b) . In 143B cell line derived tumors, Foslip was taken up significantly more efficiently than Foscan (Fig. 3a) , whereas in the K7M2L2 cell line derived tumors, the uptake of Foslip compared to Foscan was only significantly higher at 6 hr after PS administration (Fig. 3b) . Ex vivo measurements of mTHPC fluorescence in dissected tumor and healthy control leg tissue revealed a significant 2.4-and 2.7-times higher uptake of Foscan and Foslip, respectively, in 143B cell line-derived tumors than in the control tissue (Fig. 3c) . Similarly, in the K7M2L2/BALB/c model, the uptake of Foscan and Foslip by tumor tissue was 3.4-and 4-times higher, respectively, than by control tissue (Fig. 3d) . Based on these ex vivo measurements, the uptake of the two mTHPC formulations by tumor tissue was indistinguishable in both osteosarcoma mouse models.
Fluorescence microscopy of tumor tissue cryosections showed a rather uniform distribution of mTHPC fluorescence of Foscan and Foslip in both osteosarcoma mouse models. The fluorescence in adjacent muscle tissue was considerably lower than in tumor tissue in both tumor models indicating again more efficient uptake of both mTHPC formulations by tumor than by healthy tissue (Fig. 3e) .
Anti-tumor efficacy of Foscan or Foslip-based PDT in the xenograft and syngeneic osteosarcoma mouse models
We next assessed the tumor suppressive potential of Foscanand Foslip-based PDT in the two osteosarcoma mouse models. The growth of i.t. tumors derived from 143B cells in SCID mice, lacking functional T and B lymphocytes, was significantly inhibited by Foscan and Foslip-based PDT and Foslip was slightly more effective than Foscan (Figs. 4a and  4c) . Treatment-induced swelling of the tumor leg 3 days after PDT explained the observed transient increase in tumor volume. One week after PDT, the tumor volume of Foslip- Cancer Therapy and Prevention treated mice was only 1.2-times and that of Foscan-treated animals only 1.8-times larger compared to the non-treated control mice, which had a 2.2-times larger tumors compared to before PDT. Two weeks after PDT, the tumor volume of the control mice was 4-times larger than before treatment start, whereas mice subjected to Foscan and Foslip-based treatment had only a 2.6-time and 1.8-times, respectively, larger tumors compared to before PDT. The difference in tumor volume in both groups of PDT treated mice was not statistically significant.
In BALB/c mice with an intact immune system, the inhibition of tumor growth by Foscan-and Foslip-mediated PDT was even more pronounced than in SCID mice (Figs. 4b and  4d) . One week after PDT, the tumors in Foscan-or Foslipbased PDT treated mice was indistinguishable and only 2.4 times larger than before treatment compared to the nontreated control mice, which had a 7.8 times larger tumors compared to before PDT. At sacrifice of the mice, K7M2L2 cell line-derived tumors in non-treated mice were 14.3-times larger than at the beginning of the experiment. The tumors of Foscan/PDT treated animals were still only 2.7 times larger and those of Foslip/PDT treated mice only 4.7 times larger than before treatment. In contrast, two days after laser light illumination of the tumor, a swelling and edema formation in the leg where the tumor was localized was observed in all mice subjected to PDT. In the PDT study performed in the KM2L2/ BALB/c osteosarcoma model, three mice per group were sacrificed 48 hr after PDT to assess the extent of necrosis and apoptosis in the tumor tissue of treated and non-treated animals (Fig. 4e) . Overall, the level of necrosis and apoptosis was remarkably higher in the PDT-treated than in control tumors, which only showed negligible areas of necrosis and cleavedcaspase 3 staining (average necrosis histological score: 0.3; average apoptotic index: 0.02%). Despite variability among the PDT-treated tumors, Foscan/PDT treated tumors exhibited on average higher necrosis (average necrosis histological score: 4.5) and apoptosis (average apoptotic index: 7.5%) scores than those subjected to Foslip-based PDT (average necrosis histological score: 2.7; average apoptotic index: 2.6%).
The effect of Foscan and Foslip-based PDT on pulmonary metastases
To study the impact of the immune system on a putative systemic anti-tumor effect of PDT in experimental osteosarcoma, lungs were dissected at sacrifice from 143B/SCID and from K7M2L2/BALB/c mice 14 and 10 days after Foscan-or Foslipbased PDT. The number of micro-and macrometastases was assessed on the surface of lung whole mounts (Figs. 5a and 5c ). PDT with either Foscan or Foslip had no effect on pulmonary metastasis in SCID mice (Figs. 5a and 5c ). In contrast, in immunocompetent BALB/c mice, Foscan-and Foslip-based PDT significantly inhibited the formation of lung micro-and macro-metastases to a comparable extent (Figs. 5b and 5c ). Thus, in experimental osteosarcoma investigated here, PDT requires an intact immune system to provoke a systemic antitumor effect. In agreement with this, we observed significantly higher numbers of T lymphocytes at the periphery of the tumors in BALB/c mice euthanized 10 days after PDT than in controls (Figs. 5d and 5f ). The number of T lymphocytes in the core of the tumors was only significantly higher in the Foslip treated mice (Figs. 5e and 5f ). The number of B lymphocytes in the tumors was comparable among the groups (data not shown). Likewise, the numbers of B-or T-lymphocytes within the lungs were not significantly different in the PDT treated and control groups (data not shown).
PDT inhibits tumor perfusion in the syngeneic K7M2L2/ BALB/c osteosarcoma mouse model Blood perfusion of the tumor-bearing and the healthy control hind-limb was measured prior to and after Foscan-and Foslipbased PDT. The perfusion of the tumor-bearing hind limb area before PDT was on average 45.5% higher than in the corresponding hind limb area of the control leg in all experimental groups of mice (Fig. 6a) . Two days after PDT, a striking reduction of tumor perfusion was observed in the Foscan-and Foslip-based PDT treated mice (p < 0.001). Remarkably, on experimental Day 7, the perfusion in the tumors in both treatment groups recovered to levels prior to PDT (Figs. 6a and 6b) .
The effects of PDT on tumor vascularization were also investigated by histology and immunohistochemistry (Fig.  6c) . CD31-immunostained endothelial cells were virtually absent in predominantly necrotic PDT-treated tumor areas, indicating disruption of vessels. In non-necrotic areas of PDT-treated tumors CD31 immunostaining remained detectable, but at overall less density than that observed in tumor tissue not subjected to PDT, which showed moderate to high numbers of CD31-stained blood vessels.
Discussion
This study investigated the potential use of PDT in two clinically relevant models of experimental osteosarcoma as a novel approach for effective treatment of metastasizing osteosarcoma. The study compared the uptake and dark-and phototoxicity in vitro and the efficacy of PDT in vivo with mTHPC in the free formulation Foscan and the liposomal formulation Foslip. It took advantage of the orthotopic human 143B and the mouse K7M2L2 cell line, which form primary intratibial tumors and lung metastases within two weeks after inoculation in immune-defective SCID and in syngeneic immune-competent BALB/c mice, respectively.
The results of the experiments carried out in vitro, demonstrating comparable time-and dose-dependent uptake of both Foscan and Foslip in the two osteosarcoma cell lines, are in line with the results of previous studies performed in human biliary cancer cell lines. 35 Despite a slightly less efficient uptake of Foslip compared to Foscan by the two osteosarcoma cell lines over time, both compounds showed a comparable phototoxicity triggering apoptosis. Importantly, Foslip, unlike Foscan, showed hardly any dark-toxicity at the concentrations used in the present study. This later finding was again in good agreement with those of the study with the human biliary cancer cell lines 35 due to the considerable toxicity of ethanol/propandiol (data not shown), which is used as a solvent for Foscan in place of water for Foslip.
Crucial for the success of PDT in cancer therapy is a predominant uptake of PS by tumor compared to healthy tissue. This was indeed observed in vivo and ex vivo for i.v. administered Foscan and Foslip in both osteosarcoma mouse models investigated in the present study. These results confirmed a previously reported higher content of both formulations in tumor than in adjacent muscle tissue 27, 36 . Two mechanisms have been proposed to account for these findings. Both Foscan and Foslip bind to serum proteins such as albumin and high and low density lipoproteins (HDL/LDL) that facilitate their cellular uptake, which is apparently accelerated in fast proliferating cancer cells that are dependent on a high transport rate of lipoproteins. 37, 38 Increased PS uptake in tumor compared to healthy tissue is also caused by anatomical changes within the tumor, characterized by an enhanced leakiness of tumor blood vessels, and a slower lymphatic drainage, causing an accumulation of the PS in the tumor tissue, called the enhanced permeability and retention (EPR) effect. 39, 40 The results of the here reported experiments, analyzing the time-dependent uptake of mTHPC by tumor tissue, showed a significantly higher uptake of Foslip than of Foscan at all time points investigated in the 143B/SCID model and at 6 hrs after mTHPC administration in the K7M2L2/BALB/c model. These observations are consistent with the findings of De Visscher et al. who reported a significantly higher increase of Foslip than of Foscan fluorescence intensities upon i.v. PS administration in a subcutaneous adenocarcinoma mouse model. 41 Thus, Foslip appears to enhance the bioavailability of mTHPC in tumor tissue. Along these lines, it is assumed that liposomal carriers enhance the EPR effect due to the formation of larger macromolecules upon binding to plasma proteins. 42, 43 Already 20 years ago, pioneering studies performed by Korbelik et al. demonstrated the importance of an intact immune system for the efficacy of PDT. 44 A comparison of the efficacy of PDT in immune-compromised and in immune-competent mice in the present study confirmed the important findings of Korbelik et al. PDT with Foscan and Foslip only transiently inhibited the growth of intratibial 143B cell line-derived tumors in SCID mice and had no significant effect on lung metastasis. In immune-competent BALB/c mice, however, the growth of K7M2L2 cell linederived primary tumors was persistently suppressed and the formation of both micro-and macro-metastases significantly inhibited by PDT with the two PS formulations. Additionally, our findings indicate increased infiltration of T-lymphocytes at the primary tumor site, pointing to a PDT activated T cell adaptive immunity that decreases pulmonary metastasis. Altogether, the findings confirmed the important impact of an intact immune system on PDT efficacy reported by Korbelik et al. and needs to be further explored.
Due to enhanced angiogenesis in the tumor bearing leg, blood flow was significantly enhanced in all groups of mice before photodynamic treatment. Analysis of tumor vascularization and perfusion in the K7M2L2/BALB/c model demonstrated a pronounced inhibitory effect of the PDT on the blood supply of the primary tumor. These observations are consistent with reported toxic and inhibitory effects of PDT on endothelial cells and platelet formation, respectively, leading to vascular leakage and collapse and, consequently, an impaired blood flow in the treated tumor bearing leg. 11, 45, 46 However, this effect was only temporary, likely due to compensatory mechanisms in non-damaged neighboring blood vessels that restored the blood flow to levels before treatment. Since angiogenesis plays a major role in tumor progression, targeting tumor vascularization by PDT has an additional at least transient beneficial tumor suppressive effect. 47 Interestingly, in the 143B/SCID model, Foslip was more effective than Foscan, presumably due to the observed higher amounts of mTHPC accumulating in tumors of Foslip than of Foscan-treated mice and to previously reported higher concentrations of monomeric mTHPC achieved with liposomal formulations, as hydrophobic PS (Foscan) strongly aggregate in aqueous media weakening their photosensitizing efficacy. 37, 42 Differences in efficacy between Foscan-based and Foslipbased PDT was only observed in the xenograft mouse model, further studies are needed to evaluate additional treatment setting for both mTHPC formulations. The relation of the liposomal carrier system and their pharmacokinetics to PDT efficacy is still under debate. Previous studies in preclinical mammary carcinoma and fibrosarcoma models showed no correlation of the PS concentrations in the tumor and PDT efficacy, indicating a correlation between PDT efficacy and PS concentration in endothelial cells. 48, 49 On the other side, dHallewin et al. demonstrated the importance of Foslip accumulation in the tumor tissue, giving rise to the highest amount of tumor necrosis with the highest PS concentration in the tumor. 50 Our results provide a first hint that in osteosarcoma, Foslip is equally potent compared to Foscan, but to truly compare the PDT efficiency between both compounds, further studies are needed.
In summary, this study demonstrates potent mTHPC-based PDT-mediated tumor suppressive effects in two clinically relevant intratibial mouse models of osteosarcoma, and clearly demonstrates the potential of PDT to inhibit lung metastatic growth in animals with an intact immune system. Considering that PDT has a relatively low systemic toxicity, repetitive application is possible. Consequently, it is an interesting novel option for the treatment of osteosarcoma, even in combination with current standards of care including neoadjuvant chemotherapy.
